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With the increasing detection of early gastric cancer, minimally invasive treatment methods have been investigated to improve quality of life in patients with early gastric cancer while maintaining survival rates comparable to those with conventional radical gastrectomy. Endoscopic resection, a representative minimally invasive treatment for early gastric cancer, is currently recognized as the standard treatment method for this disease in selected cases [1] . Conventional endoscopic mucosal resection (EMR) for early gastric cancer has been limited to small lesions (typically < 2.0 cm) because use of EMR for larger lesions may result in piecemeal resection. To overcome this limitation, endoscopic submucosal dissection (ESD) methods have recently been developed. ESD enables en bloc resection of large lesions and those with accompanying ulcerations, as the lesion is directly dissected along the submucosal layer with a high frequency electrosurgical knife [1] . With the development of the ESD technique and the accumulation of long-term outcome data on endoscopic resection for early gastric cancer, the indications for endoscopic resection are expanding [2, 3] . Currently endoscopic resection is widely used to treat early gastric cancer and previous studies have reported excellent long-term outcomes after use of this technique [2, 3] . However, as the stomach is preserved and regional lymph nodes cannot be removed during endoscopic resection, various forms of cancer recurrence, including local, metachronous, and extragastric, can occur subsequently [4] . Local recurrence after ESD for early gastric cancer is reported to range from 0.4 % to 3.7 % [4], * Byung-Hoon Min and Eun Ran Kim contributed equally to this work.
Min Byung-Hoon et al. Surveillance strategy after curative endoscopic submucosal dissection for early gastric cancer … Endoscopy Background and study aims: To suggest an appropriate surveillance strategy after curative endoscopic submucosal dissection (ESD) for early gastric cancers, based on incidence and patterns of local, metachronous, and extragastric recurrence. Patients and methods: Between 2003 and 2011, 1497 consecutive patients with 1539 differentiated-type early gastric cancers meeting absolute or expanded indication criteria underwent curative ESD. They were followed up with esophagogastroduodenoscopy (EGD) and abdominal computed tomography (CT) under a standardized surveillance protocol. Long-term outcomes were analyzed for 1306 patients with at least 1 year's follow-up. Results: Incidences of residual and synchronous lesions detected within 1 year were 0.13 % and 0.87 %, respectively. During median 47 months of follow-up, there was 1 local recurrence (0.08 %; early gastric cancer) and 47 cases of metachronous recurrence (3.6 %; 44 early gastric cancers, 3 pT2 advanced gastric cancers); all were curatively treated. During a 5-year surveillance, the cumulative incidence curve of metachronous recurrence increased linearly. Median time from ESD to metachronous recurrence was 30 months. There were 2 extragastric recurrences (0.15 %) in lymph nodes, at 5 and 4 years, respectively, after curative ESD for absolute and expanded indications. The patient with the expanded indications underwent a palliative operation and died of gastric cancer progression.
Conclusions: There was a constant incidence rate of metachronous recurrence during a 5-year surveillance period and there was extragastric recurrence at least 4 years after ESD of early gastric cancer even for absolute indications. Therefore, annual or biannual surveillance EGD and abdominal CT might be necessary for at least 5 years after curative ESD for early gastric cancers, with absolute as well as expanded indications. and metachronous recurrence ranges from 2.7 % to 14.0 % [5] . In addition to local and metachronous recurrence, several studies have reported cases of extragastric recurrence after endoscopic resection for early gastric cancer [6 -12] . If these various forms of recurrence after endoscopic resection are not detected at an early stage, radical gastrectomy, which had been avoided for the primary lesion, would be required [4] . Invasive radical gastrectomy with lymph node dissection invariably results in severe impairment of quality of life [13] . Moreover, extragastric recurrence can lead to a fatal outcome [6, 8] . To avoid these unfavorable and sometimes lethal outcomes, an established surveillance strategy is required for the early detection of recurrence. This surveillance strategy should be based on the incidence and patterns of recurrence after endoscopic resection for early gastric cancer. Recently, the Japanese Gastric Cancer Association has proposed treatment guidelines that include follow-up protocols after curative endoscopic resection for early gastric cancer [14] . In these guidelines, annual or biannual endoscopy is recommended after curative endoscopic resection for early gastric cancer meeting the absolute indication criteria. Abdominal ultrasonography or computed tomography (CT), as well as annual or biannual endoscopy, is recommended after curative endoscopic resection for early gastric cancer that meets the expanded indication criteria. However, the follow-up schedule still varies even among Japanese institutions [4] , and a standard surveillance strategy after endoscopic resection for early gastric cancer is yet to be established. In the present study, we investigated the incidence and patterns of local, metachronous, and extragastric recurrence after curative ESD for early gastric cancers meeting the absolute or expanded indications. We suggest a surveillance strategy, based on the long-term follow-up data, to improve outcomes after curative ESD for early gastric cancer.
Patients and methods
!
Patients
Patients who underwent their first ESD for differentiated-type early gastric cancer (well or moderately differentiated early gastric cancer or papillary early gastric cancer) at Samsung Medical Center between November 2003 and May 2011 were enrolled in this study. At our institution, ESD is not indicated for poorly differentiated or signet ring cell early gastric cancers. Patients were excluded from the study population when the pathologic examination of the ESD specimen gave a diagnosis of poorly differentiated or signet ring cell early gastric cancer. In cases of multiple early gastric cancers, patients were excluded from the study population if at least one lesion was finally diagnosed as poorly differentiated or signet ring cell early gastric cancer. During the study period, a total of 1889 differentiated-type early gastric cancer lesions in 1838 consecutive patients (including 47 patients with two lesions and 2 patients with three lesions) were treated by ESD. We performed a retrospective review of outcomes after ESD for these 1838 consecutive patients, who were identified from a prospectively collected database. All ESD procedures for early gastric cancer were performed by three experienced endoscopists (B. H .M., J. H. L., and J. J. K.), based on the expanded indications [14] . The ESD procedures of our institution have been described in detail elsewhere [15] . In brief, ESD consists of three steps: (i) injecting fluid into the submucosal layer to separate it from the proper muscle layer; (ii) circumferential cutting of the mucosa surrounding the lesion; and (iii) submucosal dissection of the connective tissue under the lesion with an electrosurgical knife. All enrolled patients provided written informed consent before undergoing ESD. The study protocol was approved by the institutional review board at Samsung Medical Center.
Histopathological evaluation
ESD specimens were stretched, pinned to a polystyrene plate, and totally immersed in 10 % neutral buffered formalin for more than 12 hours for fixation. After fixation, the specimen was sectioned serially at 2-mm intervals, parallel to a line that included the closest resection margin of the specimen so that both lateral and vertical margins could be assessed. The depth of tumor invasion was then evaluated along with lymphovascular involvement and degree of differentiation [1] . Histologically, tumors were classified into differentiated-type carcinoma (well or moderately differentiated adenocarcinoma or papillary adenocarcinoma) or poorly differentiated or signet ring cell carcinoma. According to Korean and Japanese guidelines, early gastric cancers with components of both differentiated-type carcinoma and poorly differentiated or signet ring cell carcinoma were classified according to the quantitatively predominant histologic type [14, 16] .
Follow-up after ESD
Esophagogastroduodenoscopy (EGD) with a biopsy was performed 2 months after ESD, to confirm healing of the ESD-induced artificial ulcer and to exclude the presence of any residual tumor. EGD with a biopsy and abdominal CT were performed every 6 months thereafter for 3 years, to detect local, metachronous, or extragastric recurrence. From the 4th to 5th years after ESD, EGD with a biopsy and abdominal CT were performed annually. Patients with early gastric cancers meeting the absolute or the expanded indications underwent the same follow-up protocol regardless of indication.
Definitions
En bloc resection was defined as resection of the tumor in one piece with no endoscopically residual tumor. R0 resection was defined as resection of the tumor with no histological evidence of cancer cells on the lateral or vertical margins. The resection was judged as curative when all of the following conditions were fulfilled, according to Japanese gastric cancer treatment guidelines [14] :
▶ well or moderately differentiated early gastric cancer or papillary early gastric cancer; ▶ en bloc resection; ▶ negative lateral resection margins; ▶ negative vertical resection margin; ▶ no lymphovascular invasion; and ▶ (i) tumor size ≤ 2 cm, mucosal cancer, no ulcer in tumor (that is, an early gastric cancer meeting the absolute indication), or (ii) tumor size > 2 cm, mucosal cancer, no ulcer in tumor, or (iii) tumor size ≤ 3 cm, mucosal cancer, ulcer in tumor, or (iv) tumor size ≤ 3 cm, sm1 cancer (submucosal invasion depth < 500 μm from muscularis mucosa layer). Long-term outcomes after ESD, including recurrence and overall survival, were analyzed only in patients undergoing curative resection for early gastric cancers meeting the absolute or expanded indications. In cases of multiple early gastric cancers, patients were excluded from the analysis if curative resection was not achieved for at least one lesion.
A cancer detected at the primary resection site during the first or second follow-up EGD within 12 months after curative resection was regarded as a residual lesion. Local recurrence was defined when the cancer was detected at the primary resection site after at least two negative follow-up EGDs after curative ESD of the primary lesion. A new gastric cancer lesion detected at a location other than the primary resection site within 12 months after curative resection was regarded as a synchronous lesion. Metachronous recurrence was defined when a new gastric cancer lesion was detected at a location other than the primary resection site at least 12 months after curative ESD of the primary lesion. The following patients were excluded from calculation of the local, metachronous, or extragastric recurrence rate: (i) patients who underwent gastrectomy after ESD; (ii) patients with residual or synchronous lesions; or (iii) patients without at least 1 year of follow-up after ESD. Bleeding was defined as: (i) intraoperative massive bleeding that required blood transfusion; (ii) postoperative bleeding that required blood transfusion or endoscopic or surgical intervention because of hematemesis or melena; or (iii) a decrease in hemoglobin level greater than 2 g/dL, after the procedure. Perforation was diagnosed when mesenteric fat or the intra-abdominal space was observed directly during the procedure (frank perforation), or if free air was found on a plain chest X-ray after the procedure without a visible gastric wall defect having been noted during the procedure (microperforation).
Statistical analysis
Categorical data were analyzed with the χ 2 test or Fisher's exact test. Continuous data were analyzed using Student's t test. Logistic regression analysis was used to identify independent predictors of metachronous recurrence after curative ESD. Data on overall survival were obtained using the national registry of medical insurance. Overall survival was measured from the date of ESD to the date of death from any cause or to the censoring date of May 31 2014. Overall survival rates were calculated using the KaplanMeier method and were analyzed using the log rank test. A P value less than 0.05 was considered to be statistically significant. Fig. 1 ). Within 1 year after curative resection, residual lesions were noticed in 2 patients (0.13 %, 2/1497; 2 early gastric cancers), and synchronous lesions were found in 13 patients (0.87 %, 13/1497; 12 early gastric cancers, 1 one advanced gastric cancer confined within the muscularis propria layer). All cases of residual lesions and synchronous lesions were curatively treated with ESD or surgery.
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Overall survival rate after curative ESD
After exclusion of patients with residual or synchronous lesions, of patients undergoing gastrectomy after ESD, and of patients without at least 1 year of follow-up, 1306 patients with 1341 differentiated-type early gastric cancers were finally included in the analysis of long-term outcomes after curative ESD. The Kaplan-Meier overall survival curve is shown in• " Fig. 2 . The median duration of follow-up for overall survival after curative ESD was 61 months (range 17 -122 months). The 5-year overall survival rates of patients with early gastric cancers-meeting absolute and expanded indications, respectively, were 97.3 % and 96.4 %. There was no significant difference in overall survival between the two groups.
Recurrence
After curative ESD for early gastric cancer, patients underwent follow-up EGD and abdominal CT to detect local, metachronous, and extragastric recurrence. The median duration of follow-up for detecting recurrence after curative ESD was 47 months (range 13 -111 months).
Local recurrence
During the follow-up period, local recurrence was detected in only 1 patient (0.08 %, 1/1306). The patient was a 69-year-old woman and had an early gastric cancer that met the absolute indication criteria (1.8-cm tumor confined within the muscularis mucosa layer) and was located at the proximal antrum near the angle. She had undergone en bloc resection of the primary lesion, and local recurrence was detected 19 months after curative ESD. This locally recurrent tumor was treated by curative radical gastrectomy. Pathologic examination of the surgical specimen revealed that the recurrent tumor was confined within the muscularis mucosa layer. No lymph node metastasis was found in the surgical specimen. SD, standard deviation. 1 If patients had multiple tumors including both absolute-indication and expanded-indication early gastric cancer, data from the expanded-indication tumor were used. If patients had multiple tumors including only absolute-indication cancers or only expanded-indication cancers, data from the largest tumor were used. 2 sm1, submucosal invasion depth < 500 μm from muscularis mucosa layer.
Metachronous recurrence
Metachronous recurrence occurred in 47 patients (3.6 %, 47/1306) after curative ESD of the primary lesion. The cumulative incidence curve for metachronous recurrence is shown in • " Fig. 3 . During the 60-month surveillance period after curative ESD, the cumulative incidence curve revealed a nearly linear increase, implying a constant incidence rate of metachronous recurrence. The median time from ESD to metachronous recurrence was 30 months (range 13 -75 months). Among the 47 cases of metachronous recurrence, 44 were early gastric cancers and 3 were advanced gastric cancers confined within the muscularis propria layer (pT2 cancer). The metachronous pT2 advanced gastric cancers were detected 22, 30, and 60 months after ESD. All the cases of metachronous recurrence were curatively treated. Curative ESDs were performed for 28 cases of differentiated-type metachronous early gastric cancer. Radical gastrectomies were done for 10 cases of differentiated-type early gastric cancer, 6 cases of poorly differentiated or signet ring cell early gastric cancer, and 3 cases of pT2 advanced gastric cancers. Among the 19 cases treated with gastrectomy, 2 patients with pT2 advanced gastric cancer showed regional lymph node metastasis. When cases with and without metachronous recurrence were compared, multiple lesions and well differentiated histology were found significantly more frequently in cases with metachronous recurrence (• " Table 2 ). In multivariate analysis, both multiple lesions and well differentiated histology were identified as independent predictors of metachronous recurrence (• " Table 2 ).
Extragastric recurrence
During the follow-up period, we encountered 2 cases of extragastric recurrence after curative ESD (0.15 %, 2 /1306) (• " Table 3 , Present study, summarizes the details). The first patient (patient #1 in• " Table 3 , Present study;• " Fig. 4 a -e) underwent curative ESD for an early gastric cancer meeting the absolute indication criteria and located at the angle. The primary lesion had not shown histological heterogeneity with a poorly differentiated or signet ring cell carcinoma component. In a 61-month follow-up CT after ESD, two enlarged perigastric lymph nodes were noticed that had not been present in the 49-month follow-up CT done 12 months previously. The 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) image showed hypermetabolic lesions in the corresponding lymph nodes found at CT. No local recurrence was detected at the 61-month follow-up EGD after ESD. The patient underwent curative radical subtotal gastrectomy with D2 lymph node dissection 63 months after ESD. Postoperative pathologic examination confirmed metastasis in two regional lymph nodes. In addition, a gastric specimen revealed intragastric local recurrence around the ESD scar area. Tumor cells had invaded into the submucosa, muscularis propria, subserosa, and serosa layers. However, no tumor cells were found in the mucosal layer.
The second patient (patient #2 in • " Table 3 , Present study;
• " Fig. 4 f -4 j) underwent curative ESD for an early gastric cancer meeting the expanded indication and located at the antrum. The primary lesion had not shown histological heterogeneity. At the 48-month follow-up CT after ESD, several enlarged lymph nodes were detected around the common hepatic artery and right gastroepiploic vessels. These enlarged lymph nodes had not been present in the 36-month CT taken 12 months previously. The 18 F-FDG PET image showed hypermetabolic lesions in the corresponding lymph nodes seen at CT. The patient underwent radical subtotal gastrectomy with D2 lymph node dissection 49 months after ESD. The operative findings showed metastatic lymph nodes encasing the superior mesenteric vein and invading the pancreas; therefore, surgery was performed palliatively. No intragastric recurrence was found in the gastric specimen. After palliative surgery, the patient received chemotherapy but died of gastric cancer progression 66 months after the initial ESD. Months after endoscopic resection Fig. 3 Metachronous recurrence after curative endoscopic submucosal dissection (ESD) for early gastric cancer: cumulative incidence curve. During the 60-month surveillance period after curative ESD, the cumulative incidence curve showed a nearly linear increase, implying a constant incidence rate for metachronous recurrence. 
Discussion
!
The major advantage of endoscopic resection, compared with radical gastrectomy, for early gastric cancer is that the stomach is preserved and therefore the patient's quality of life is much less impaired [1, 13] . However, as the stomach is saved, local and metachronous recurrence can occur after ESD. In addition, endoscopic resection has a major limitation in that regional lymph nodes cannot be removed during the procedure, entailing the risk of extragastric recurrence. If these various forms of recurrence after endoscopic resection are not detected at an early stage, invasive radical gastrectomy would be required and even mortality is possible, especially in cases of extragastric recurrence. Therefore, an established surveillance strategy is required for the early detection of recurrence. Previous studies on surveillance after endoscopic resection for early gastric cancer were limited in that the surveillance schedule varied among participating institutions and the various forms of recurrence were not systematically evaluated [4, 5, 17] . To overcome these limitations, we systematically assessed the incidence and patterns of local, metachronous, and extragastric recurrence after curative ESD for early gastric cancer, under a uniform standardized protocol. In the present study, residual lesions were detected in two patients (0.13 %, 2 early gastric cancers), and synchronous lesions were found in 13 patients (0.87 %, 12 early gastric cancers, 1 pT2 advanced gastric cancer) within 1 year after ESD. One case of local recurrence (0.08 %, early gastric cancer) was found 19 months after curative en bloc ESD. All cases of residual lesions, synchronous lesions, and local recurrence were curatively treated as they were all found at an early stage, except for one case of pT2 advanced gastric cancer. Although local recurrence usually occurs in cases of piecemeal resection [17, 18] , previous large studies have reported the occurrence of local recurrence even in patients having en bloc with R0 resection [2, 4] . In these cases, metachronous early gastric cancer occurring just adjacent to the primary ESD site could be mistaken for local recurrence. In the present study, the cumulative incidence curve of metachronous recurrence revealed a nearly linear increase during the 60-month surveillance period after curative ESD, implying a constant incidence rate of metachronous recurrence. This finding was consistent with the results of previous studies [4, 19] . After 60 months after ESD, however, the slope of the cumulative incidence curve decreased compared with the slope of the initial phase. Considering established precancerous changes such as atrophy or intestinal metaplasia and the possibility of field cancerization in the preserved stomach [20, 21] , this decrease in incidence might be due to the decreased frequency of follow-up EGD after the 5-year surveillance period rather than a real decrease in metachronous recurrence. In the present study with annual or biannual followup EGD, nearly all cases of metachronous recurrence were found at an early stage (44 early gastric cancers and 3 pT2 advanced gastric cancers), and therefore all cases were treated. There was regional lymph node metastasis in the surgical specimens from 2 of the 3 patients with pT2 advanced gastric cancers. Given established precancerous changes in the preserved stomach, the intragastric recurrence pattern after ESD, and the high rate of CI, confidence interval; SD, standard deviation. 1 If patients had multiple tumors including both absolute-indication and expanded-indication early gastric cancer, data from the expanded-indication tumor were used. If patients had multiple tumors including only absolute-indication cancers or only expanded-indication cancers, data from the largest tumor were used. 2 sm1, submucosal invasion depth < 500 μm from muscularis mucosa layer Table 3 Extragastric recurrence after curative endoscopic resection for differentiated-type early gastric cancer, in the present study and in the published literature. μm from muscularis mucosa layer. 2 Palliative operation because of direct invasion of lymph node with metastasis into superior mesenteric vein. 3 Death from liver metastasis after surgery.
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Original article early detection of intragastric recurrence under our follow-up protocol, annual or biannual follow-up EGD might be necessary for at least 5 years after curative ESD for early gastric cancer.
In the present study, presence of multiple lesions and well differentiated histology were identified as independent predictors of metachronous recurrence. Previous studies have reported that multiple lesions and well differentiated histology were features of gastric cancer with microsatellite instability [22, 23] . There have been several studies showing a high rate of metachronous recurrence in gastric cancers with microsatellite instability [24] . Hasuo et al. [24] reported that metachronous recurrence occurred after endoscopic resection in 67 % of gastric cancer cases with microsatellite instability. In gastric cancer cases without microsatellite instability, however, the incidence of metachronous recurrence was only 7 %. Another predictive biomarker of metachronous recurrence was CD44 variant 9, the cell surface marker associated with cancer stem-like cells [25] . Hirata et al. reported that metachronous recurrence rates were 77 % and 6 % in gastric cancers with and without CD44 variant 9 expression, respectively [25] . One major issue in metachronous recurrence after endoscopic resection for early gastric cancer is the effect of Helicobacter pylori infection. Two recent large prospective randomized trials have shown contradictory results. In a Japanese study, the metachronous recurrence rate was 6.5 % during a 3-year follow-up, and patients receiving H. pylori eradication treatment showed significantly lower metachronous recurrence rates than patients without eradication therapy (3.5 % versus 9.6 %, P = 0.003) [19] . In a Korean study, the metachronous recurrence rate was 3.1 % during a 3-year follow-up, and metachronous recurrence rates were comparable in patients with and without H. pylori eradication treatment (2.3 % versus 3.9 %, P = 0.24) [26] . Both studies were limited in that metachronous recurrence was not distinguished from synchronous lesions. At our institution, H. pylori eradication is not routinely performed after ESD because of the limited coverage of the Korean medical insurance system. During the study period, the presence of H. pylori infection was mainly investigated histopathologically, which might be influenced by interobserver variability. As these factors could result in bias, data on H. pylori infection were not presented in the present study. Further studies are required to identify the exact role of H. pylori infection and to validate the role of predictive biomarkers such as microsatellite instability and CD44 variant 9 in metachronous recurrence. During the study period, we encountered two cases of extragastric recurrence (one patient had been treated because of an absolute-indication early gastric cancer and the cancer in the other patient met the expanded indication). In contrast to the favorable treatment results in cases of intragastric recurrence, in one patient the extragastric recurrence was found to be at an inoperable stage and the patient died of gastric cancer progression. In this patient, the extragastric recurrence in lymph nodes was first detected as enlarged lymph nodes at the 48-month follow-up CT after curative ESD. These enlarged lymph nodes had not been present in the 36-month follow-up CT done 12 months previously. In a literature review, we found 6 other cases of extragastric recurrence after curative endoscopic resection for differentiated-type early gastric cancers (• " Table 3 , Literature review). Among these 6 cases (1 absolute indication, 5 expanded indication), metastases to lymph nodes occurred in 5 and peritoneal seeding was found in 1. In Japan, where endoscopic resection is recognized as the standard treatment for early gastric cancer, imaging studies for extragastric recurrence are not recommended for patients with early gastric cancers meeting the absolute indication criteria [14] ; abdominal CT or abdominal ultrasonography is recommended only for patients treated under expanded indication criteria [14] . Several Japanese hospitals have far narrower indications for imaging studies and they recommend abdominal CT or ultrasonography only for patients with expandedindication early gastric cancer with submucosal invasion [4] . As mentioned above, however, extragastric recurrence has been reported following curative endoscopic resection for even absolute-indication early gastric cancer [11] . Furthermore, more than half of the reported cases with extragastric recurrence were mucosal cancers, and one patient with mucosal cancer died of gastric cancer progression (case #2 in • " Table 3 , Literature review) [6, 9 -11] . In cases of advanced gastric cancer, it is well known that most recurrences usually occur within 3 years after radical gastrectomy [27] . In cases of early gastric cancer curatively treated by endoscopic resection, however, the extragastric recurrence occurred at least 4 years after endoscopic resection in half of the reported cases (2 patients in the present study and case #5 and case #6 in • " Table 3 , Literature review) [7, 8] . This might reflect the slow growth features of early compared with advanced gastric cancers [28] . Given these findings associated with extragastric recurrence and the risk of mortality, annual or biannual abdominal CT might be necessary for at least 5 years after curative ESD in cases of absolute-indication as well as expanded-indication early gastric cancer. As most extragastric recurrences occur in lymph nodes, abdominal ultrasonography, which has limited ability to detect enlarged abdominal lymph nodes, might be inappropriate as a surveillance tool [14] . In the present study, the incidence of extragastric recurrence after curative ESD for early gastric cancer was 0.15 %. As mentioned above, 6 additional cases have been published in the literature [6 -11] . Considering publication bias, there may be more cases of extragastric recurrence than these, and the incidence of extragastric recurrence might be underestimated. As the incidence rate is low, predictive factors for extragastric recurrence after curative endoscopic resection for early gastric cancer currently have not been identified. One plausible candidate is histological heterogeneity mixed with a poorly differentiated or signet ring cell carcinoma component. In fact, previous surgical studies have reported a significantly higher rate for lymph node metastasis rate in differentiated-type early gastric cancers with histological heterogeneity compared with pure differentiated-type early gastric cancers [29, 30] . Interestingly, however, these studies consistently reported that there was no case of lymph node metastasis when differentiated-type early gastric cancers with histological heterogeneity met curative resection criteria for early gastric cancer according to either absolute or expanded indications. As extragastric recurrences have been reported in 2 patients with early gastric cancer with histological heterogeneity [6, 7] , further studies are required to evaluate the influence of histological heterogeneity on extragastric recurrence after curative endoscopic resection for early gastric cancer. The present study is limited in that it was performed at a single tertiary referral center and had a retrospective design. However, it also has several strengths. First, the study population was large, and the study participants were consecutively enrolled from a prospectively collected database. Second, among 1497 patients undergoing curative resection, 88 % (1321/1497) participated in the follow-up program after ESD. Third, follow-up after curative ESD was performed using a uniform standardized protocol. Fourth, the median duration of follow-up after curative endoscopic resection was 47 months. Based on this large long-term standardized follow-up data in patients undergoing curative ESD, we suggest the following surveillance strategy after curative ESD for early gastric cancer. First, given the constant incidence rate of metachronous recurrence during the 5-year surveillance period, established precancerous changes such as atrophy or intestinal metaplasia in the preserved stomach, and the high rate of early detection of intragastric recurrence under our follow-up protocol, annual or biannual surveillance EGD is recommended for at least 5 years after curative ESD for early gastric cancer. Second, given the extragastric recurrences even in the cases of early gastric cancer meeting the absolute indication and of mucosal early gastric cancer, and given the slow growth features of early gastric cancer leading to late recurrence, annual or biannual abdominal CT is recommended for at least 5 years after curative ESD in cases of absolute-indication as well as expanded-indication early gastric cancer.
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